Form 4: Gilead Sciences Director Acquires Shares and Options

Director Sandra Horning of Gilead Sciences acquired 1,146 restricted stock units and 4,884 stock options on April 30, 2026, with immediate vesting.

Summary

• Director Sandra Horning of Gilead Sciences, Inc. acquired 1,146 restricted stock units (RSUs) and 4,884 stock options on April 30, 2026.
• The RSUs represent the contingent right to receive one share of Gilead Sciences' common stock and vested immediately upon grant.
• The stock options also vested immediately upon the grant date.
• Following these transactions, Horning beneficially owns 6,293 shares of common stock directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a director acquiring equity, which can be interpreted as a sign of confidence, but it does not provide new financial performance data.

Positives

• Director acquisition of company stock and options can signal confidence in the company's future prospects.
• Immediate vesting of RSUs and stock options suggests a reward for past performance or a commitment to future service.
• The acquisition of 1,146 RSUs and 4,884 stock options by a director indicates a significant equity stake increase.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on a transaction by a director.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a director of Gilead Sciences, are closely watched by the market as they can provide insights into management's perception of the company's valuation and future performance. The acquisition of equity by a director often suggests a positive outlook.

Stakeholder Impact

• Shareholders may view the director's acquisition of stock and options positively, potentially signaling confidence in the company's future performance.
• Employees may see this as a sign of stability and commitment from leadership.
• Creditors and suppliers are unlikely to be directly impacted by this insider transaction.

Key Dates

Keywords

Gilead Sciences, GILD, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director, Beneficial Ownership, Equity Incentive Plan